Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-05

Clinical Trial Update: Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea [Phase 1, Phase 2]

View source ↗

Summary

Open-label study assessing secukinumab for papulopustular rosacea in Phase 1/2 completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Anne Chang | Conditions: Papulopustular Rosacea | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-05